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Factor Concentrates for Treatment of Hemophilia: Which One to Choose?
By Doreen B. Brettler and Peter H. Levine
U NTIL THE ADVENT of components that could more
specifically replace specific missing clotting factors,
patients with hemophilia were treated with whole blood and
then plasma. Such patients had a shortened lifespan and
were crippled with severe anthropathy; many died of hemon-
rhage. With the discovery in 1960 that factor VIII:C was
concentrated in cryoprecipitate, more specific replacement
for persons with factor FVIII deficiency was possible. In the
early 1 970s, further purification processes were discovered,
and lyophihized concentrates of higher purity, both factor
VIII and pnothnombin complex concentrates (PCCs), began
to be produced.
Lyophilized concentrates revolutionized the care of
patients with hemophilia. In home therapy programs,
patients were taught to infuse the concentrate in the home
setting at the earliest sign of hemorrhage.’ The long-term
effects of hemorrhage were decreased, days lost from work or
school and days of hospitalization decreased, and lifespan
gradually increased until the AIDS era.2’3 Lyophilized con-
centrate of clotting factors are prepared from plasma
obtained from 2,000 to 30,000 donors. Infectious complica-
tions from transfusion-transmitted viruses began to be noted
in patients with hemophilia in the late 1970s and are still a
major concern. Many newer types of factor concentrates are
being produced, both to eliminate infectious side effects and
increase purity. This review first describes the complications
associated with concentrate infusion and then reviews the
various factor concentrate products currently available for
treatment of hemophilia and their advantages and disadvan-
tages. The treatment of patients with inhibitors is beyond the
scope of this review and is the subject of several recent
articles.4’5
COMPLICATIONS OF CONCENTRATE INFUSION
Hepatitis B
The hepatitis B virus (HBV), non-A, non-B hepatitis virus
(NANB), and the human immunodeficiency virus (HIV)
remain the major agents described to date that are transmit-
ted through concentrate infusions. Acute hepatitis B infec-
tion with elevated liver function tests and jaundice is uncom-
mon in hemophilia but -90% of patients infused before the
advent of heat-treated concentrates have developed antibody
to hepatitis B (HB5Ab), indicating past exposure through
factor concentrate. A small percentage of patients (5% to
10%) have become chronic carriers of hepatitis B (HB5Ag
positive), which may make them more prone to develop
chronic liven disease or carcinoma of the liven.6 Delta hepati-
tis (HDV), a virus that requires the presence of HBV as a
carrier, is also a potential risk to persons with hemophilia
since the virulence of HBV infection may be increased. Even
with newer methods of viral attenuation (discussed below),
infection with hepatitis B still occurs. Thus, we strongly
recommend that all newly diagnosed patients with hemo-
phihia receive the hepatitis B vaccine. In a newly diagnosed
infant, immunizations should be started soon after birth.
NANB Hepatitis
NANB hepatitis (NANBH) is a common infectious com-
plication associated with factor infusions and may lead to
fatal complications. Although it is still a diagnosis of exclu-
sion since no specific serologic test exists, the majority of
hemophiliac patients (90% to 100%) who infuse concentrate
have either persistently or intermittently elevated liver
enzymes which probably represent the consequences of
NANBH.7’8 In a series of I 55 unselected liver biopsies
reviewed, 22% of cases had chronic active hepatitis or
cirrhosis.9 This study, however, could not relate the etiology
ofadvanced liver disease solely to NANBH. In another study
in 35 patients selected because ofabnormal enzymes, 44 liver
biopsy samples showed chronic active hepatitis or cirrhosis in
20 samples. Advanced liver disease did not correlate with
degree of elevations of aminotransferases.’#{176} Schimpf et al
performed 52 biopsies on 45 patients with hemophilia; 29%
had progressive liven disease.” Thus, NANBH may repre-
sent a potential long-term problem for persons with hemo-
philia. Studies on NANBH secondary to blood transfusions
imply that -20% ofpatients with elevated liver function tests
will develop chronic liven disease, including cirrhosis.’2
AIDS
HIV infection is a more recent problem; the virus was
introduced into the blood supply in the late 1970s. The first
cases of AIDS in hemophiliac patients were reported in
l982.’ Since then, there have been >800 cases of AIDS in
hemophiliac patients. In addition, -70% of patients with
hemophilia have antibody to HIV. They include those
patients who received factor concentrates before i984/I985
and patients treated only with cryoprecipitate or fresh-frozen
plasma. By epidemiologic and viral culture data, HIV sero-
positivity in such persons is consistent with latent infection.’4
Even in the asymptomatic patient, HIV seropositivity has
caused immune dysfunction, with decreased CD4 cell levels
and decreased helper/suppressor cell ratios.’5 Whether all or
most persons infected with HIV will contract AIDS is not yet
clear, but hemophiliac patients, especially those infected
after age 22 years who have been seropositive for at least 7
years have a >40% probability of contracting AIDS.’6 In
vitro evidence shows that exposure to other viruses can
activate HIV that has been latent within monocytes.’7 Lym-
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phocytes already activated by other antigens may be more
susceptible to infection by HIV.’8 In addition, HIV in
latently infected cells may be activated by multiple cyto-
kines.’9 Thus, theoretically, a concentrate free of all blood-
borne viruses might have advantages even to hemophiliac
patients previously infected with HIV.
Alloanligens in Factor Concentrates
Factor concentrate itself, perhaps secondary to the large
amount of foreign protein present, may cause alterations in
the immune systems of hemophiliac patients. Since detailed
immunologic studies were not done routinely on the hemo-
phihia population before the I980s when I-IIV infection
became widespread, evidence that immune dysfunction pre-
dated HIV infection is sporadic. In Scotland, Ludlam et al
reported that in a group of HIV antibody-negative patients
receiving factor VIII concentrates prepared locally by the
Scottish Transfusion Service and not yet contaminated by
HIV, 43% of the recipients demonstrated a decreased CD4/
CD8 ratio secondary to decreased CD4 levels.20 These abnor-
mahities appeared to be related to treatment with factor
concentrate. They did not correlate with abnormalities in
liver function tests, although most of these patients had
elevated alanineamino transferase (ALT). A group of our
HIV-senonegative patients have minor immune abnonmahi-
ties with decreased percentages of CD4 cells and decreased
helper/suppressor cells.’5 In addition, in a group of 97
patients with severe/moderate hemophilia A, studied for
skin test anengy, anengy correlated more strongly with inten-
sity of factor infusion than with the presence or absence of
antibody to HIVs.2’ In vitro studies have also shown that
intermediate-purity factor concentrates themselves sup-
pressed a mixed lymphocyte reaction whereas more highly
purified preparations did not, although the exact mecha-
nisms have not been defined.22
Additional Complications of Concentrates
Other complications of factor concentrate include typical
allergic reactions of urticania and temperature elevations
which are uncommon. Rarely, anaphyhaxis has been
reported. Factor concentrates also may contain isoagglutin-
ins (anti-A or anti-B) and when administered to patients
with blood types A or B (especially in large amounts as
occurs during and after surgery) may cause significant
hemolysis. In 1979, decreases in single-breath carbon mon-
oxide diffusion capacity in a group of hemophiliac patients
was believed to be secondary to lodging of particulate matter
from the concentrate in the pulmonary capillary bed.23
Subsequently, a syndrome of primary pulmonary hyperten-
sion was described in five patients with severe hemophilia
using large amounts of concentrate.24 Again, the mechanism
was not elaborated but may have resulted from particulate
matter or immune complexes being deposited in the lungs or
from other immune-mediated reactions.
An additional side effect of prothrombin complex concen-
trates (PCCs) and activated prothrombin complex concen-
trates (aPCCs) not noted with factor VIII concentrates is
that of thrombosis, including deep venous thrombosis, pul-
monany embolus, and myocardial infarction.25 This risk is
small but measurable especially in a patient undergoing
orthopedic surgery who may require bed rest for prolonged
periods of time. The thromboses are believed to be secondary
to activated factor VII and X found in PCC preparations,
although this has not been proven. Most physicians who treat
hemophilia administer prophylactic subcutaneous hepanin to
the patient receiving large amounts of PCC who will not be
ambulatory. Thus, infusion of factor concentrate can be
associated with a variety of complications (Table 1).
VIRUCIDAL TREATMENTS OF CONCENTRATES
There is now a triple barrier to viral transmission through
factor concentrates: (a) self-exclusion for donors, (b) donor
screening, and (c) viral inactivation procedures. Self-exclu-
sion includes the asking of detailed questions concerning
hepatitis, possible HIV exposure, and general health ques-
tions regarding nonspecific symptoms of HIV infection.
Donor screening now includes testing for ALT elevations and
hepatitis B core antibody (HBcAb) which are surrogate tests
for NANBH and which are believed, in tandem, to decrease
the incidence of transmission of NANBH by 61%.26 A
serologic test for NANBH is currently under development by
Chinon (Emonyville, CA). Ifproven reliable, it should greatly
enhance not only screening of infected units but also diag-
nosis of NANBH. Testing of the donor for HIV antibody is
also done. Any abnormal plasma units with ALT elevation,
HIV antibody, or HBcAb are discarded.
Donor screening for HIV does not provide a necessarily
safe unit. Experience with blood transfusion shows that HIV
may be transmitted by anti-HIV-negative blood if the donor
is in the process of senoconversion. The risk of HIV infection
from such an HIV-negative unit may be from I in 5 1 ,000 to 1
in 102,000.27 Blood, however, is not exposed to any viral-
attenuating methods.
Multiple methodologies for inactivating viruses during
processing of factor concentrate have been devised. Heat
treatment is currently the most commonly used procedure.
Efficacy of this method is dependent on (a) temperature; (b)
duration of heat treatment; (c) presence of clotting factor
stabilizers which may also stabilize virus; and (d) the method
of heat treatment [whether the concentrate is heated when
lyophihized (“dry heat treated”) or heated while in suspen-
sion or solution (“wet heat treated”) which appears to be
more effective]. Dry heat methods include heating for 30 to
72 hours at temperatures from 60 to 68#{176}C.Recently, a
Table 1 . Complications of Factor Concentrate
Infectious
Hepatitis B/delta hepatitis
Non-A, non-B hepatitis
HIV
Parvovirus
? HTLV-I
Mild immunosuppression
Allergic reactions
Hemolysis secondary to isoagglutinins
Primary pulmonary hypertension
Thromboses (only with PCCs and APCCs)
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“super dry heat” method has been used in which heating
occurs at 80#{176}Cfor 72 hours. Wet heating methods include
suspension of the concentrate in n-heptane followed by
heating at 60#{176}Cfor 20 hours (Alpha, S Pasadena, CA),
vapor suspension followed by heating at 60#{176}Cfor 10 hours at
190 mbar plus a one-hour 80#{176}Ctreatment at 370 mbar
(Immuno, Vienna), and heating in solution for 10 hours at
60#{176}C(“pasteurized,” Behringwerke [Marbung, W Gen-
many], Cutter [Berkeley, CA]).
In addition to heat-treatment methods chemical methods
are used to inactivate virus. Use of solvent/detergent combi-
nations which disrupt lipid-coated viruses such as HIV and
hepatitis virus is being studied by the New York Blood
Center and the American Red Cross. The New York Blood
Center is using 0.3% tni-n-butyl phosphate (TNBP) as the
solvent and 0.2% sodium cholate28 as the detergent; the
American Red Cross/Hyland is using 0.3% TNBP and 1%
Triton X-lOO. In Europe, for PCC products, f3-pnopniolac-
tone and ultraviolet (UV) light are used to kill virus. This
method has not been licensed in the United States.
A third method for eliminating virus from concentrate
involves affinity chromatography with a mouse monoclonal
antibody (MoAb) to either FVIII:VWF or FVIII:C attached
to solid-phase aganose support. Cryoprecipitate is used as the
starting material, and several purification steps are pen-
formed. A much higher purity factor VIII:C concentrate
results (specific activity >3,000 U/mg protein before addi-
tion of albumin stabilizer). Moreover, when model viruses
such as Sindbis virus and pseudonabies are placed in the
starting material, a significant log kill occurs with the
chromatography procedure itself. HIV is also reduced signif-
icantly by this process.29 The product is either heat-treated in
the final dry state at 60#{176}Cfor 30 hours (Monoclate, Armour,
Horsham, PA) or is initially treated with TNBP/Tniton
X-lOO (Hemophil M, Hyland, Glendale, CA). A third
product, now in phase 2 trials, is pasteurized after MoAb
affinity chromatography. The various types of viral inactiva-
tion procedures, the pharmaceutical company producing
them, and the brand names are shown in Table 2.
Because animal models, especially for NANBH, are not
available, human trials with concentrates are needed to prove
viral safety. To show whether a specific concentrate is free of
hepatitis B, NANB, on HIV, studies using previously
untransfused patients, mostly newly diagnosed infants, are
undertaken.
The International Committee on Thrombosis and Hemo-
stasis (ICTH) has set forth criteria for constructing clinical
trials to evaluate the viral safety of new concentrates.3#{176}
Subjects must have had no previous blood transfusions
including cryoprecipitate and must have normal baseline
values for ALT. They must be senologically negative for HIV
and hepatitis B unless they have been vaccinated; if they
have, HBAb positivity is acceptable. Testing for ALT must
be performed at 2-week intervals so that elevations are not
missed and sampling should continue at this interval for 4
months. Multiple lots of the new concentrate should be
tested, and at least 20 patients should be enrolled so that the
probability that a concentrate carries NANBH even with a
completely negative study is decreased.
Table 2. Commercial Factor VIII Concentrates and Viral
Inactivation Method Used
Viral Inactivation
Method
Name of
Concentrate Manufacturer
Heat
Heating in lyophilized
state-dry heat
60#{176}Cfor 32 h Factor Vlll-HT Armour
60#{176}Cfor 72 h Hemophil-T Hyland
68#{176}Cfor72h KoateHT Cutter
Super dry heat
80#{176}Cfor 72 h UK National
Health Servicet
Vapor heating AHF-vapor heated Immunot
Heating in suspension Profilate-HT Alpha
with heptane 60#{176}Cfor (wet method)
20 h
Heating in aqueous solu- Koate-HS Cutter
tion (pasteurization) Humate-P Behringwerke
60#{176}Cfor lOh
Solvent/detergent
TNBP/cholate Factor Vlll-SD NY Blood Center
Purification by affinity chro-
matography
60#{176}Cfor 30 h in lyophi- Monoclate Armour
lized state
TNBP/Triton X-100 in Hemophil M Hyland
“wet’ ‘ state
60#{176}Cfor 10 h in aqueous Monoclate M Armourt
solution (pasteurization)
#{149}Productno longer available.
tAvailable in Europe only.
tNow in therapeutic trials.
New onset of infection with hepatitis B or HIV after a
concentrate is infused can be demonstrated with serologic
assays. Documenting infection with NANB virus is more
difficult since no serologic tests yet exist; thus, infection is
still a diagnosis of exclusion. NANBH is inferred if a
subject’s ALT levels rise to greaten than two and one-half
times normal after a concentrate infusion and remain ele-
vated for at least 2 weeks after the initial abnormal measure-
ment. New serologic tests for NANB virus may make
diagnosis of NANBH no longer one of exclusion.
Hepatitis
EVALUATION OF VIAAL SAFETY TRIALS
Most presently available products have been in clinical
trials using previously untransfused hemophiliac patients as
described above. However, although it is beyond the scope of
this review to analyze each trial individually, certain trials
have used patients treated previously with cryoprecipitate or
other single-donor blood fractions, have small numbers, or
have not obtained ALT levels at regular close intervals. Each
clinical trial should be evaluated critically by the persons
treating hemophilia before they make decisions on safety.
One of the results of the trials to date is to confirm that the
NANB virus as well as the hepatitis B virus is difficult to
inactivate. In three trials using “dry heat” concentrate
 For personal use only. at UNIV OF MASSACHUSETTS on April 3, 2008. www.bloodjournal.orgFrom 
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heated from 60 to 68#{176}Cfor 30 to 72 hours,3133 16 of 21
subjects developed NANBH as defined by the ICTH. How-
ever, in one trial using concentrate dry heated at 80#{176}Cfor 72
hours, none of 32 subjects developed NANBH.34 Thus,
heating the concentrate in the lyophihized state does not
appear to kill NANBH virus uniformly unless, perhaps,
heating is done at high temperatures. No hepatitis B
occurred in these studies.
“Wet-heated” concentrates are products heated either in
suspension or in solution (pasteurized). In one trial of 18
subjects using factor VIII concentrate suspended in heptane,
four contracted NANBH.35 In another trial with vapor-
treated concentrate, none of 24 subjects contracted
NANBH.36 With use of the pasteurization method, no cases
of NANBH were reported in 26 patients.’#{176} Thus, treatment
of concentrate with vapor or in solution appears to have
decreased the incidence of NANBH. However, with the
vapor-treated concentrate, four patients developed markers
consistent with hepatitis B infection. Several cases of HBV
were also reported “off study” in patients using the pasteur-
ized product, which emphasizes once more that all newly
diagnosed patients with hemophilia should be vaccinated
against HBV.
The viral safety trials with concentrates using the solvent/
detergent method and the affinity chromatography method
are still ongoing. With New York Blood Center concentrate
(TNBP/sodium cholate), none of I 5 subjects have developed
NANBH,37 although the trial did not adhere to the ICTH
criteria.30 With MoAb affinity chromatography techniques,
none of 35 previously untransfused subjects have yet devel-
oped NANBH.38’39
HIV
HIV is heat labile. No seroconvensions have occurred in
any of the viral safety trials in which HIV antibody status
has been studied. However, I 8 cases of HIV seroconversion
have occurred with dry-heat--treated factor VIII concentrate
infused between 1985 and l987.#{176} No case was involved in
viral safety trials. Twelve seroconvensions were associated
with a single brand of concentrate using dry heating at 60#{176}C
for 30 hours. This product was subsequently withdrawn from
the market. Some of the above cases also involved use of
concentrate for which plasma unscreened for HIV had been
used. In four of the remaining cases, dry-heat--treated con-
centrate of other manufacturers was also used; some lots
were HIV antibody screened and others were not. One of
these four patients, however, received dry-heated concen-
trate for which all plasma had been screened. In one case, the
patient received both concentrate heated in the lyophihized
state and in suspension, and in the remaining case the patient
received only concentrate heated in suspension with n-
heptane using plasma from unscreened donors.
Although the above cases are anecdotal reports, either dry
heat at higher temperatures for longer periods of time or
concentrates vapor treated or heat treated in solution (pas-
teunized) appear to be the most efficacious in killing HIV.
The solvent-detergent methods as well as purification by
affinity chromatography also appear to be safe with regard
to HIV infection, although data are still being collected. As
for the HIV seroconvensions described above, most pharma-
ceutical companies have (a) discarded concentrate previ-
oushy produced with HIV-unscneened plasma, and (b)
stopped production of dry-heat-treated concentrate. Both
actions, especially the latter, have begun to create an interna-
tional shortage of factor concentrates, especially factor
VIII.
In summary the newer products appear to have increased
viral safety, especially those heat treated in solution or
purified with MoAbs. Table 3 summarizes the trials. With
the ability to clone the factor VIII gene, two companies
(Genentech[S San Francisco]/Cutter, Genetics Insti-
tute[Cambnidge, MA]/Hyland) are now producing recom-
binant factor VIII concentrate for limited human trials. The
advent of this technology may, we hope, eliminate transmis-
sion of human blood-borne viruses.
HIGHLY PURIFIED CONCENTRATES
Concentrates purified using MoAb affinity chromatogra-
phy have a final specific activity of factor VIII:C of -3,000
U/mg protein. Even after albumin is added as a stabilizer,
the purity is still significantly higher than previously avail-
able products, and many extraneous human proteins have
been removed. These products are clearly efficacious. In a
group of seven patients treated with a highly purified product
for >24 months, clinical efficacy was excellent, as was
half-life (T’/2) and recovery.4’ No inhibitors against factor
VIlI:C developed in these patients and no allergic reactions
were noted. In a larger study involving 33 previously untrans-
fused patients, three patients developed factor VIII inhibi-
tons,39 a percentage in the expected range. Whether
increased purity of concentrate may lead to increased devel-
opment of inhibitors is unknown.
Since large amounts of extraneous proteins such as
immune complexes, aggregated immunoglobuhins and the
living or killed viruses may be additionally suppressive to the
immume system of a hemophiliac patient, concentrates that
have only factor VIII:C and albumin may be less immuno-
suppressive.42 Theoretically this would be beneficial not only
to previously untransfused patients but also to HIV-seroposi-
tive patients. In vitro experiments have shown that at a
standard milligram-per-milliliter concentration (either in
terms of protein concentration on units of factor VIII), factor
Table 3. Summary of Viral Safety Trials
With Factor VIII Concentrates
Viral Inactivation Process
No. of Patients Who
Acquire Wal Infection
NANBH HBV HIV
Dryheat
Superdryheat
Pasteurized
Suspension/heptane
Vapor treated
Solvent/detergent
Affinity chromatography dry heat
Affinity chromatography
solvent detergent
16/21 - 0/21
0/32 0/32 0/32
0/26 0/10 0/26
4/ 1 8 0/ 1 8 0/18
0/24 4/14 0/28
0/1 6 - 0/17
0/1 8 - 0/18
0/ 1 7 - 0/17
Published in abstract form.
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VIII concentrate made with affinity chromatography meth-
ods did not inhibit lectin-induced lymphocyte proliferation
whereas conventional AHF concentrates did.22 Similar
experiments have shown decreased mixed lymphocyte neac-
tions as well, using conventional concentrates rather than
highly purified concentrates. Other experiments have shown
that intermediate purity factor VIII concentrates may sup-
press monocyte function by downregulating Fc receptors.42
Whether high-purity concentrates affect the immune sys-
tem in vivo is not known. In the seven HIV-senopositive
patients described above who have received a high-purity
concentrate for >2 years, CD4 levels have stabilized, and in
three of seven patients skin test anergy has been reversed.4’
These three patients initially had no positive skin test reac-
tions and at the end of 2 years reacted to at least two
antigens. However, no controlled study comparing the effects
over time on the immune system of the newer purer concen-
trates to the more conventional intermediate-purity concen-
trates has been completed; two such studies are now ongoing.
This is of great importance since stabilization of the immune
system would be of significant benefit to HIV-infected
individuals.
With regard to factor IX concentrates, a plasma-derived
preparation devoid of factors II, VII, and X, and viral
attenuated, is currently being used in clinical trials. Comphi-
cations of thrombosis that occasionally occur in postopera-
tive hemophilia B patients may be eliminated with these
types of products.
Pharmaceutical companies are beginning to use conven-
tional chromatographic techniques to produce purer concen-
trates from plasma without using MoAbs. Thus, production
of virus-free concentrates with less extraneous protein may
be possible at lower cost.
WHICH CONCENTRATE TO CHOOSE
All concentrates now available in the United States are
viral inactivated. Most pharmaceutical companies in the
United States have withdrawn dry-heat-treated concen-
trates. Thus, the current choices involve use of either concen-
tnates heat treated in suspension or solution, concentrates
viral-attenuated using solvent/detergent methods, on con-
centrates more highly purified with MoAbs plus viral macti-
vated. Although data suggest that the more highly purified
products may produce stabilization of the immune system in
individuals who are already HIV infected, conclusive evi-
dence does not exist. However, because interaction with
other viruses such as herpes virus or hepatitis viruses may at
least in in vitro systems activate latent intracellular HIV,’7
the best viral-attenuated products perhaps should be admin-
istered to all persons with hemophilia, especially those who
are HIV infected. This is controversial because some physi-
cians believe that individuals who are already HIV infected
should receive concentrates less intensively heat treated and
therefore less costly.43
We believe that a pasteurized or monocbonally purified
product can be used for previously untreated and infre-
quently treated hemophiliac persons and persons who are
free of HIV infection. More data on the solvent/detergent
concentrates with respect to transmission of NANBH needs
to be accumulated, but they also appear to be safe. For
HIV-seropositive patients, concentrates that are viral macti-
vated and highly purified offer theoretical benefits. Unfontu-
nately, factors other than scientific are also now involved in
such a choice. The first is supply. There is now a national
shortage of factor VIII concentrates which may last for
many months. The reasons for this are multifactonial and
include withdrawal of most dry-heat-treated products from
the market, decreased yields of factor obtained with the more
intense viral inactivation and purification procedures, and
collapse of the albumin market which had helped defray the
cost offactor VIII concentrates. First, even ifa physician or a
patient requests a specific product, it may not be available.
Second, expense is an issue. Because of the more sophisti-
cated extraction methods, the lower final yields, and the loss
of profit from albumin, concentrates currently are four to ten
times more expensive than in previous years. How third-
party insurers will deal with these new price increases is
unclean, although early experience is remarkably encourag-
ing. Both the National Hemophilia Foundation and individ-
ual physicians are attempting to find solutions to these
complex supply and financial problems.
NEW APPROACHES
Cloning of the factor VIII:C and IX gene provides many
possibilities for treatment and perhaps eventual cure of
hemophilia. Two factor VIII concentrates using recombinant
technology and thus eliminating the need for collection of
human plasma are available for experimental purposes. Both
products are now undergoing human clinical trials. Data
suggest that in two patients who have been using one such
product for at least I year, T’/2 and recovery are excellent,
and no adverse effects have been noted.” Because the VIII:C
is expressed from a hamster-derived cell line, we must be
concerned about traces ofanimal protein in the material even
though affinity chromatography with mouse MoAb has
apparently removed most such contaminants. We must also
be concerned with the stability of the gene in the fermenta-
tion system. However, freedom from human virus, eventual
large supply, and ultimate low cost are all probable future
benefits. Although this material is currently technologically
difficult to produce in large amounts, it as well as a recombi-
nant factor IX concentrate may be widely available in 2 to 3
years.
Currently, liver transplantation offers a cure for hemo-
phihia, albeit a somewhat impractical one. In a series of four
patients with hemophilia reported from Pittsburgh, who
required liver transplantation because of end-stage liver
disease, three survived the inital surgery and then normalized
their factor VIII:C levels and required no further replace-
ment. Cloning of the genes for factor VIII and IX and
recombinant genetic technology may allow “gene therapy”
and eventually cure of this disease.
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